Global Anti-Depressants Drugs Market Analysis

Global Anti-Depressants Drugs Market Analysis


$ 3999

The global Anti-Depressants drugs market size was valued at $16.44Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $26 Bn in 2030. drug class, indication, route of administration, end-user, distribution channel and geography. The global Anti-Depressants drug market will grow because of the development of novel antidepressant drugs and the expansion of the product portfolio of pharmaceutical companies. The key market players are H. Lundbeck A/S (DNK), GlaxoSmithKline plc (GBR), Eli Lilly and Company (USA), Janssen Pharmaceuticals (BEL), Pfizer Inc. (USA), AstraZeneca (GBR), Bristol-Myers Squibb (USA), and others.

ID: IN10GLPH051 CATEGORY: Pharmaceuticals GEOGRAPHY: Global AUTHOR: Chandani Patel

Buy Now

Global Anti-Depressants Drugs Market Executive Summary

The global Anti-Depressants drugs market size was valued at $16.44 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $26 Bn in 2030. Depression is a common mental health disorder characterized by persistent feelings of sadness, loss of interest or pleasure, changes in appetite and sleep patterns, low energy, and difficulty in concentrating. Depression can have a significant impact on an individual's daily life, including their ability to work, socialize, and function in relationships.

According to the World Health Organization (WHO), mental health expenditure is a crucial aspect of the healthcare system, as it determines the availability, accessibility, and quality of mental health services. The WHO recommends that countries allocate at least 5% of their healthcare budget to mental health, but many countries fall short of this target. Global mental health expenditure varies widely across countries and regions. In low-income countries, mental health expenditure is often very low, with many countries spending less than 1% of their healthcare budget on mental health. In contrast, high-income countries tend to spend more on mental health, with some countries spending over 10% of their healthcare budget on mental health.

The prevalence and incidence of depression vary depending on the region, age, gender, and other demographic factors. According to the World Health Organization (WHO), depression is a leading cause of disability worldwide, affecting over 264 Mn people globally. Depression is one of the most common mental health disorders globally, with an estimated 4.4% of the world's population experiencing depression at any given time.

The incidence of depression is highest among young adults, with an estimated 15% of people experiencing depression at some point during their lifetime. Depression is more common among women than men. According to the WHO, the prevalence of depression in women is nearly twice as high as in men. The highest rates of depression are found in the Eastern Mediterranean and Western Pacific regions, while the lowest rates are found in the African region. Depression can have a significant impact on an individual's quality of life, leading to disability, loss of productivity, and increased healthcare costs. It is estimated that depression and anxiety disorders cost the global economy over $1 trillion annually.

One of the primary treatments for depression is the use of antidepressant medications, which are drugs that help regulate mood and reduce symptoms of depression. The market for antidepressant drugs has been growing steadily over the years, driven by the increasing prevalence of depression and the rising demand for effective treatments. The impact of depression on the antidepressant drugs market is significant. As the prevalence of depression continues to increase, the demand for antidepressant drugs is expected to grow. In addition, the growing awareness about mental health issues and the availability of effective treatments are also driving market growth.

global anti depressants drugs market

Market Dynamics

Market Growth Drivers Analysis

The antidepressant drugs market is primarily driven by the increasing prevalence of depression and other mental health disorders globally. According to the World Health Organization (WHO), depression is a leading cause of disability worldwide, affecting over 264 million people globally. As a result, there is a growing demand for effective treatments, including antidepressant drugs, to manage the symptoms of depression. The rising awareness about mental health issues and the availability of effective treatments are also driving the market growth.

In addition, the development of novel antidepressant drugs and the expansion of the product portfolio of pharmaceutical companies are also driving the growth of the market. The increasing investment in research and development activities, the emergence of personalized medicine, and the growing trend of combination therapies are expected to create new growth opportunities for the market.

Market Restraints

There are many market restraints as well one of them is the increasing availability of generic versions of antidepressant drugs. Generic drugs are cheaper than branded drugs, which can reduce the overall revenue generated by the market. In addition, the potential side effects of antidepressant drugs, including weight gain, nausea, and dizziness, can affect patient compliance and adherence to treatment.

Moreover, the stringent regulatory requirements for the approval of antidepressant drugs can also pose a challenge to market growth. The complex and time-consuming clinical trials, high development costs, and increasing regulatory scrutiny can delay the approval and launch of new antidepressant drugs.

Competitive Landscape

Key Players

  • H. Lundbeck A/S (DNK)
  • GlaxoSmithKline plc (GBR)
  • Eli Lilly and Company (USA)
  • Janssen Pharmaceuticals (BEL)
  • Pfizer Inc. (USA)
  • AstraZeneca (GBR)
  • Bristol-Myers Squibb (USA)
  • Teva Pharmaceutical Industries Ltd. (ISR)
  • Mallinckrodt (GBR.)
  • Sun Pharmaceutical Industries Ltd. (IND)
  • Novartis AG (CHE)
  • Endo Pharmaceuticals plc (GBR)
  • Zydus Cadila (IND)
  • Mylan N.V. (USA.)
  • Mayne Pharma Group Limited (AUS)
  • Amneal Pharmaceutical Inc (USA)
  • Avet Pharmaceuticals Inc. (USA)
  • Aurobindo Pharma (IND)
  • WOCKHARDT (IND)
  • Currax Pharmaceuticals LLC (IND)

Recent developments

June 2021: An agreement to jointly develop and market zuranolone (SAGE-217), which is intended for major depressive disorder, postpartum depression, and other psychiatric illnesses, was made public by Sage Therapeutics and Biogen Inc.

February 2021: On-demand mental healthcare provider Ginger recently announced a cooperation with online pharmacy Capsule. This collaboration sought to deliver anti-depressants and other mental health prescriptions to Ginger members at their homes.

November 2020: Biogen Inc and Sage Therapeutics announced a collaboration agreement to develop and commercialize zuranolone (SAGE-217) indicated for major depressive disorder, postpartum depression and other psychiatric disorders.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

Regulations regarding the development, approval, and use of antidepressant drugs differ across the globe, as each country has its own regulatory framework for pharmaceutical products. Here are some examples of the regulatory agencies and guidelines for antidepressant drugs in different regions.

United States:

The Food and Drug Administration (FDA) regulates the approval and marketing of antidepressant drugs in the United States. The FDA requires that all new drugs undergo rigorous clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The FDA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

In the United States, most antidepressant drugs are covered by private insurance plans and government programs such as Medicare and Medicaid. The extent of coverage and cost-sharing requirements may vary depending on the specific insurance plan or program.

European Union:

The European Medicines Agency (EMA) is responsible for the evaluation and approval of antidepressant drugs in the European Union. The EMA requires that all new drugs undergo clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The EMA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

In the European Union, reimbursement policies for antidepressant drugs vary by country. Most European countries have a national healthcare system that covers the cost of antidepressant drugs for eligible patients. However, the specific reimbursement policies and cost-sharing requirements may vary depending on the country.

Japan:

The Pharmaceuticals and Medical Devices Agency (PMDA) regulates the approval and marketing of antidepressant drugs in Japan. The PMDA requires that all new drugs undergo clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The PMDA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

China:

The National Medical Products Administration (NMPA) regulates the approval and marketing of antidepressant drugs in China. The NMPA requires that all new drugs undergo clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The NMPA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Depressants Drugs Market Segmentation

Drug Class

The market is divided into monoamine oxidase inhibitors, atypical antidepressants, tricyclic, serotonin, and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and others based on pharmacological class. In 2021, the selective serotonin reuptake inhibitors (SSRIs) market segment held the biggest market share. The strength of the pipeline of top players to assess new potential candidates in this drug class, combined with the clinical advantage of SSRIs over conventional medications in the management and treatment of depression, is anticipated to accelerate the segment's growth.

  • Tricyclic Antidepressants (TCAs) - Amitriptyline (Elavil), Amoxapine (Asendin), Desipramine (Norpramin), Doxepin (Silenor), Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)
  • Selective Serotonin Reuptake Inhibitors (SSRIs) - Citalopram (Cipramil), Dapoxetine (Priligy), Escitalopram (Cipralex), Fluoxetine (Prozac or Oxactin), Fluvoxamine (Faverin), Paroxetine (Seroxat), Sertraline (Lustral), Vortioxetine (Brintellix)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) - Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima), Venlafaxine (Effexor XR)
  • Monoamine Oxidase Inhibitors (MAOIs) - Socarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate)
  • Serotonin Antagonist and Reuptake Inhibitors (SARI) - Etoperidone (Axiomin, Etonin), Lorpiprazole (Normarex), Mepiprazole (Psigodal), Nefazodone (Serzone, Nefadar), Trazodone (Desyrel)
  • Others

Indication

By Indication, the major depressive disorder segment was the major contributor in 2021 and is expected to maintain its lead during the forecast period, owing to an increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.

  • Major Depressive Disorder
  • Anxiety Disorders
  • Attention Deficit Hyperactivity Disorder
  • Others

Route of Administration

Based on the route of administration the market is segmented into:

  • Oral
  • Injectable
  • Others

End-Users

Based on end users the market is segmented into:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

Hospital pharmacies, retail pharmacies, and online pharmacies are the three types of pharmacies that make up the market based on the distribution channel. In 2019, the hospital pharmacies segment dominated the world market. Nonetheless, the expansion of the retail pharmacy market might be attributed to patients' increasing demand for these establishments. Due to the growing prevalence of online pharmacies in emerging countries, the segment of online pharmacies is estimated to see a profitable CAGR over the forecast timeframe.

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 12 October 2023
Updated by: Jay Dalwadi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up